Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Signs SelectMDx Distribution Deal in Central, South America

NEW YORK (GenomeWeb) – MDxHealth announced today that it has signed a deal to distribute its SelectMDx for Prostate Cancer test in various countries in Central and South America.

Under the terms of the agreement, Uruguay-based biotechnology company SouthGenetics will have the rights to distribute SelectMDx in Argentina, Bolivia, Chile, Columbia, Ecuador, Mexico, Peru, the Dominican Republic, Panama, Paraguay, Uruguay, and Venezuela.

Further terms of the deal were not disclosed.

"MDxHealth is pleased to have this opportunity to provide SelectMDx testing for patients throughout Latin America through this collaborative agreement with SouthGenetics, helping to improve both the quality of care and outcomes for those suspected of harboring prostate cancer throughout Latin America," MDxHealth CEO Jan Groen said in a statement.

MDxHealth recently announced that it has also signed a distribution agreement with The European Health Centre Innovation for both the SelectMDx and ConfirmMDx for Prostate Cancer tests in Poland.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.